Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEDALUS: Durvalumab and Chemo-RT in Stage III NSCLC
NCT05128630Phase 2Unknown
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Oct 2021
- Primary completion
- Nov 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab in non-small cell lung carcinoma (NSCLC), sponsored by IRCCS San Matteo Foundation. Primary endpoint: Safety at 6 months. Status: unknown.
02
Drugs
durvalumab
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT05128630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05128630.